BIMEKIZUMAB IMPROVED KEY PATIENT-REPORTED SYMPTOMS OF AXIAL SPONDYLOARTHRITIS INCLUDING SPINAL PAIN AND FATIGUE: RESULTS FROM TWO PHASE 3 STUDIES

被引：0

作者：

Bird, Paul ^{[1
]}

Mease, Philip J. ^{[2
,3
]}

Deodhar, Atul ^{[4
]}

Dougados, Maxime ^{[5
]}

Dubreuil, Maureen ^{[6
]}

Magrey, Marina ^{[7
]}

Marzo-Ortega, Helena ^{[8
]}

Rudwaleit, Martin ^{[9
,10
,11
,12
]}

de la Loge, Christine ^{[13
]}

Ellis, Alicia ^{[14
]}

Fleurinck, Carmen ^{[13
]}

Oortgiesen, Marga ^{[14
]}

Taieb, Vanessa ^{[15
]}

Gensler, Lianne S. ^{[16
]}

机构：

[1] Univ New South Wales, Sydney, NSW, Australia

[2] St Joseph Hlth, Swedish Med Ctr Providence, Seattle, WA USA

[3] Univ Washington, Swedish Med Ctr Providence, Seattle, WA 98195 USA

[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[5] Hop Cochin, Dept Rheumatol, Paris, France

[6] Boston Univ, Sch Med, Dept Rheumatol, Boston, MA 02118 USA

[7] Case Western Reserve Univ, Univ Hosp Cleveland, Cleveland, OH 44106 USA

[8] Univ Leeds, Leeds Teaching Hosp NHS Trust & Leeds Inst Mol Me, NIHR Leeds Biomed Res Ctr, Leeds, W Yorkshire, England

[9] Univ Bielefeld, Klinikum Bielefeld, Bielefeld, Germany

[10] Klinikum Bielefeld, Bielefeld, Germany

[11] Charite, Berlin, Germany

[12] Univ Ghent, Ghent, Belgium

[13] UCB Pharma, Brussels, Belgium

[14] UCB Pharma, Raleigh, NC USA

[15] UCB Pharma, Colombes, France

[16] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

INTERNAL MEDICINE JOURNAL | 2023年 / 53卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ARA-P29

引用

页码：24 / 25

页数：2

共 50 条

[41] Resolution of enthesitis and peripheral arthritis with bimekizumab in patients with axial spondyloarthritis: Week 52 results from the BE MOBILE 1 and BE MOBILE 2 Phase 3 studies
Ramiro, S.
Poddubnyy, D.
Mease, P. J.
Lopez-Medina, C.
Fleurinck, C.
Kim, M.
Massow, U.
Taieb, V
Vyncke, L.
Wenzel, Kragstrup T.
McGonagle, D. G.
SWISS MEDICAL WEEKLY, 2023, 153 : 23S - 24S
[42] Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials
Strober, Bruce
Sigurgeirsson, Bardur
Popp, Georg
Sinclair, Rodney
Krell, James
Stonkus, Sigitas
Septe, Marcis
Elewski, Boni E.
Gottlieb, Alice B.
Zhao, Yang
Tran, Mary H.
Karpov, Alexander
McLeod, Lori D.
Mordin, Margaret
Papavassilis, Charis
Nyirady, Judit
Lebwohl, Mark
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2016, 55 (04) : 401 - 407
[43] BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
Baraliakos, X.
Navarro-Compan, V.
Poddubnyy, D.
Dubreuil, M.
Bennett, A.
Jans, L.
Massow, U.
Fleurinck, C.
Vaux, T.
Ellis, A.
De Peyrecave, N.
Maksymowych, W. P.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 357 - 358
[44] SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES
Poddubnyy, D.
Gensler, L. S.
Mease, P. J.
Orbai, A. M.
Warren, R. B.
Ink, B.
Massow, U.
Assudani, D.
Fleurinck, C.
Shende, V.
Smith, J.
Peterson, L.
White, K.
Landewe, R. B. M.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1686 - 1687
[45] Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies
Kristensen, Lars Erik
Tillett, William
Nash, Peter
Coates, Laura C.
Mease, Philip J.
Ogdie, Alexis
Gisondi, Paolo
Ink, Barbara
Prickett, Adam R.
Bajracharya, Rajan
Taieb, Vanessa
Lyris, Nikos
Lambert, Jeremy
Walsh, Jessica A.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2024, 16
[46] SUSTAINED IMPROVEMENT IN CLINICAL OUTCOMES AND LONG-TERM SAFETY OF BIMEKIZUMAB IN PATIENTS ACROSS THE SPECTRUM OF AXIAL SPONDYLOARTHRITIS UP TO WEEK 52: RESULTS FROM TWO PHASE 3 STUDIES
Gaffney, Karl
McKay, Neil D.
Sengupta, Raj
Fleurinck, Carmen
de la Loge, Christine
Massow, Ute
Taieb, Vanessa
Zhao, Sizheng Steven
Marzo-Ortega, Helena
RHEUMATOLOGY, 2024, 63
[47] RAPID IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK RESULTS OF A PHASE 3 DOUBLE BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY
Sieper, J.
Kivitz, A.
van Tubergen, A.
Deodhar, A.
Coteur, G.
Woltering, F.
Landewe, R.
VALUE IN HEALTH, 2013, 16 (03) : A227 - A227
[48] Sustained improvement in clinical outcomes and long-term safety of bimekizumab in patients across the spectrum of axial spondyloarthritis up to week 52: results from two phase 3 studies
Gaffney, Karl
McKay, Neil D.
Sengupta, Raj
Fleurinck, Carmen
de la Loge, Christine
Massow, Ute
Taieb, Vanessa
Zhao, Sizheng Steven
Marzo-Ortega, Helena
RHEUMATOLOGY, 2024, 63
[49] Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Magrey, Marina Nighat
van de Sande, Marleen
Breban, Maxime
Van den Bosch, Filip
Fleurinck, Carmen
Massow, Ute
De Peyrecave, Natasha
Vaux, Thomas
Baraliakos, Xenofon
Marzo-Ortega, Helena
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1030 - 1032
[50] BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
Magrey, M.
Van de Sande, M. G. H.
Breban, M.
Van den Bosch, F.
Fleurinck, C.
Massow, U.
De Peyrecave, N.
Vaux, T.
Baraliakos, X.
Marzo-Ortega, H.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 876 - 877

← 1 2 3 4 5 →